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Letter to the Editors: 
 
Aspirin, the most commonly prescribed antiplatelet agent in clinical practice, forms a 
cornerstone of management in patients with established cardiovascular disease 
(CVD).  The clinical efficacy and safety of aspirin when prescribed for secondary 
prevention is supported by a robust evidence base demonstrating a 24% reduction in 
mortality and a 25% reduction in serious adverse events without any increase in 
bleeding complications in the context of an acute myocardial infarction [1]. 
Nevertheless, numerous studies have shown that the antiplatelet effect of aspirin is 
not uniform and is often sub-optimal in a sizable proportion of patients [2, 3]. 
Inadequate platelet inhibition following the administration of aspirin is associated with 
recurrent cardiovascular events and adverse outcomes in patients with  coronary 
artery disease [2].   
 
Dual antiplatelet therapy (DAPT) in the form of aspirin and a P2Y12 inhibitor has 
proven benefit for the prevention of atherothrombotic complications in both stable and 
high-risk patients [4]. However, despite the initiation of DAPT, up to 20% of patients 
experience a recurrent ischaemic event within a year of their index presentation and 
in non-ST-elevation myocardial infarction (NSTEMI) mortality at five years is 22% [5].  
 
This ongoing residual ischemic risk has led to significant interest in the area of anti-
platelet treatment failure. Much of this focus has recently been aimed at overcoming 
the perceived limitations associated with the P2Y12 inhibitor clopidogrel (an agent with 
significant pharmacokinetic and pharmacodynamic variability in-vivo). The 
development and adoption of more potent P2Y12 inhibitors (i.e. ticagrelor and 
prasugrel) which provide faster, greater and more consistent levels of platelet 
 3 
inhibition has led to lower recurrent ischaemic events and cardiovascular mortality [6, 
7].  Irrespective of the P2Y12 inhibitor under investigation, the pivotal landmark DAPT 
clinical trials were all undertaken with aspirin as the background anti-platelet agent of 
choice.  Whilst the default duration of treatment for DAPT is 12 months, the long term 
clinical utility and implications of a sub-optimal response to aspirin monotherapy 
following discontinuation of the P2Y12 inhibitor after this 12-month period have been 
largely under explored. 
 
In the absence of a universally accepted definition, the concept of aspirin resistance 
is difficult to define and reported prevalence ranges from 5.5% to 61% depending on 
the patient group studied and the technique used to measure aspirin activity [3].  This 
reduced aspirin responsiveness has been shown to be associated to adverse clinical 
events in the short to medium term [2].  In clinical practice, quantitative assessment of 
the degree of aspirin induced platelet inhibition is readily available using the Verify-
Now system (Accriva, San Diego, Ca).  Using this device aspirin resistance units 
(ARU) of    550 indicates a poor response and thereby high on treatment platelet 
reactivity (HPR) [8]. Little is known about the importance of relative aspirin resistance 
over a long time-course. We sought to investigate whether the impact of VerifyNow 
determined response to aspirin, even at levels that were previously thought to indicate 
an adequate antiplatelet response, is prognostically important in terms of all-cause 
mortality at 10 years. 
 
We performed a single centre, prospective, observational study of 224 patients 
admitted with NSTEMI undergoing coronary angiography. Patients were followed up 
for a period of 120 months (10 years) for the primary end point of survival at 10 years, 
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expressed as all-cause mortality.  The study was approved by the local research ethics 
committee and conducted in accordance with the principles of the Declaration of 
Helsinki. All patients gave written informed consent prior to inclusion. Mortality data 
were obtained from the United Kingdom Office of National Statistics to determine the 
patients’ vital status at 10 years following the index admission. 
 
Aspirin-naïve patients were administered an oral loading dose of aspirin 300mg and 
maintained on aspirin 75mg daily thereafter. In line with contemporary 
recommendations at that time, all patients were administered an oral loading dose of 
clopidogrel 300mg daily and maintained on clopidogrel 75mg daily for 12 months only. 
The degree of inhibition of platelet reactivity following the administration of aspirin was 
assessed using the point of care VerifyNow Aspirin assay and expressed as ARU 
(Accriva, San Diego, Ca).  
 
 
The mean time between administration of an aspirin loading dose (or aspirin on 
admission) to angiography was 4.9  2.7 days, reflecting practice in 2007/8. Of this 
group 54% (n = 122) underwent PCI and stent implantation. Baseline clinical 
characteristics and cardiovascular risk factors, in relation to tertiles of aspirin-effect 
(expressed as ARU) are presented in Table 1.  All three groups were well matched for 
baseline characteristics and cardiovascular risk factors. Patients in T1 (ARU 363 -405) 
tended to be younger than those in T2 (ARU 406 – 436) and T3 (ARU 437 -596). 
Although not of statistical significance, a difference was also noted in the number of 
diabetic patients within each tertile, with a greater proportion in T2 and T3.   
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The effect of high on aspirin platelet reactivity on long term survival is shown in figure 
1, with higher ARU values associated with increased mortality (log rank, p = 0.009).  
Whilst diabetes is known to adversely impact on platelet reactivity following the 
administration of aspirin, a sub-group analysis of our non-diabetic cohort indicates that 
the difference in all-cause mortality observed is not driven by diabetic status alone, 
since a statistically significant difference was also observed in non-diabetic patients 
(log rank, p = 0.005).  A cox regression analysis demonstrated that age at presentation 
(HR = 1.098, 95% CI [1.05 – 1.14], p < 0.0001) in addition to HTPR (according to the 
current definition of ARU ≥ 550) at angiography (HR = 3.03, 95%CI [1.38 – 6.99], p = 
0.009), were statistically significant predictors of mortality at 10 years. Both cox-
regression and ROC analyses (c-statistic > 0.70) demonstrate that ARU values as low 
as 406 are associated with reduced long-term survival. 
 
Our study is the first to determine the clinical significance of aspirin related platelet 
reactivity at the time of angiography on longer-term survival in patients presenting with 
NSTEMI.  We demonstrate that ARU values lower than the previously defined cut off 
(ARU  550) are associated with reduced survival when assessed over this extended 
follow up period. Our findings challenge the current clinical paradigm that aspirin 
resistance is a dichotomous variable which might lead patients to be at increased 
short-term risk of recurrent cardiovascular events. In our cohort of high risk NSTEMI 
patients investigated with in-patient coronary angiography, our results suggest a 
continuum of risk related to aspirin related platelet activity. Patients in the second and 
third tertile (i.e. ARU above 406) had significantly increased mortality at 10 years, 
compared to those in tertile 1 (log rank, p=0.009).  
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Recent publications have highlighted the benefit of extended duration or additional 
antithrombotic therapies in patients with established cardiovascular disease at high 
ischaemic risk [9, 10]. These studies lend support to the concept that aspirin 
monotherapy is insufficient to prevent atherothrombotic events in a significant number 
of patients with chronic coronary syndrome. Aspirin responsiveness may be a simple 
way of identifying such high-risk individuals who may benefit from additional 
pharmacotherapies, whilst avoiding bleeding risk due to the use enhanced 
antithrombotic medication in low risk patients. 
 
Several limitations of the present study should be mentioned.  Our analysis represents 
a single centre experience of the assessment of platelet reactivity in a relatively small 
number of aspirin treated patients. Platelet reactivity following the administration of 
aspirin is assessed using only a single platelet function assay (VerifyNow) at a single 
time point (the time of in-patient angiography) and may be due to heightened platelet 
reactivity secondary to an ACS event. We have limited data regarding on-going 
adherence to prescribed secondary prevention therapy, and have assumed that all 
patients have continued to receive and be adherent to secondary prevention 
medications, including aspirin. Our follow up results at 10 years are limited to vital 
status only and we do not have information regarding recurrent ischaemic events or 
bleeding complications. 
 
In conclusion, the anti-platelet effect of aspirin, when measured early in patients with 
high risk NSTEMI, predicts survival at 10 years. Levels of platelet response previously 
thought to be adequate indicate significant ongoing risk of mortality. This simple 
measurement of aspirin responsiveness at the time of index presentation might 
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identify a sub-group of patients in which further optimisation and intensification of their 
antithrombotic treatment regime may be warranted. 
 
Table 1: Baseline characteristics, cardiovascular risk factors, patient therapy, 
procedural characteristics and medications on discharge for troponin positive 
NSTEMI patients expressed according to tertiles of platelet reactivity. 
 
 T1 (n = 76) T2 (n = 76) T3 (n = 72) p-value 







Sex (male) 52 (68) 48 (63) 52 (72) 0.494 
Risk Factors 
Diabetes 9 (12) 16 (21) 20 (28) 0.057 
Hypertension 36 (47) 46 (61) 43 (60) 0.153 
Current Smoker  20 (26) 22 (29) 22 (31) 0.603 
Previous MI 15 (20) 22 (29) 21 (29) 0.346 
Previous CABG 3 (4) 5 (7) 4 (6) 0.779 
Previous TIA/Stroke 3 (4) 7 (9) 5 (7) 0.440 
Positive FHx 32 (42) 37 (49) 32 (44) 0.717 
Hypercholesterolaemia 33 (43) 45 (59) 37 (51) 0.125 
Patient Therapy 
PCI 46 (61) 44 (58) 33 (46) 0.162 
Medical management 17 (23) 21 (28) 21 (28) 0.613 
CABG 8 (11) 11 (14) 11 (14) 0.139 
Normal coronary 
arteries 
5 (6.5) 0 (0) 2 (3) 0.065 
PCI characteristics 
Single vessel  39 (51) 46 (61) 20 (26) 0.010 
Two vessel 5 (7) 3 (4) 8 (11) 0.022 
Triple vessel 1 (1) 0 (0) 1 (1) 0.470 
BMS 15 (20) 15 (20) 12 (16) 0.619 
DES 32 (42) 34 (45) 18 (24) 0.701 
Medication on discharge 
Beta-blocker 54 (71) 58 (76) 53 (74) 0.675 
ACE inhibitor 60 (79) 53 (70) 50 (70) 0.405 
Statin 72 (95) 72 (95) 70 (97) 0.445 
Aspirin 73 (96) 73 (96) 70 (97) 0.883 
Clopidogrel 63 (83) 72 (95) 63 (91) 0.034 
Values are expressed as mean  standard deviation, frequency (%). MI = myocardial 
infarction, CABG = coronary artery bypass graft, TIA = transient ischaemic attack, FHx = 
family history of premature cardiovascular disease, PCI = percutaneous coronary 






Figure 1: Kaplan-Meier curve demonstrating the impact of the degree of 
inhibition of platelet reactivity following the administration of aspirin (expressed 
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